2023-11-12 18:56:38
The pharmaceutical company Novo Nordisk has released study details supporting the positive effects of their weight reducer drug Wegovy in preventing heart attacks. The Danish company presented the data at a congress of the US Heart Society in Philadelphia, demonstrating that treatment with a dosage of 2.4 milligrams of the drug reduced the risk of cardiovascular disease regardless of age, gender, ethnicity, or baseline body mass index.
The study results have been well-received by experts and analysts, with the company expecting to file for approval for relevant indications in the US and EU. The positive effect of Wegovy sets in quickly, and the company expects decisions on approval for these indications to be made in 2024.
The announcement comes after Novo Nordisk had previously announced that Wegovy was superior to the standard treatment for preventing serious cardiovascular complications such as strokes and heart attacks, reducing the risk by a fifth. This news led to a price jump of over 17% on the stock market in just one day.
The Danish company’s stock price has skyrocketed by around half this year alone, with Novo Nordisk currently having a market capitalization of almost 420 billion euros, making it the largest company in the Stoxx 50 Europe. Analysts are optimistic about the potential use of Wegovy against cardiovascular diseases, although there is some concern about the drug’s high price.
Overall, the data presented by Novo Nordisk at the US Heart Society congress points to the potential of Wegovy as a weight reducer in preventing heart attacks, with the company planning to seek approval for this indication over the next few years.]
#Novo #Nordisk #share #Study #details #Wegovy #underline #positive #effect